News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2022

5 May, 2022 Egetis initiates build-up of medical affairs and the commercial team with the appointment of three senior leaders News Corporate Information Other Corporate Information English IR Optional
28 April, 2022 Egetis Therapeutics publishes prospectus relating to the Rights Issue News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
26 April, 2022 Interim report January-March 2022 News English Regulatory MAR Report Interim Q1 IR Optional
20 April, 2022 Egetis Therapeutics’ 2021 annual report published News English Regulatory VPML Report Annual IR Optional
13 April, 2022 Bulletin from extraordinary shareholders’ meeting in Egetis Therapeutics AB and publication of timetable relating to the rights issue News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
6 April, 2022 Egetis announces that the recruitment target has been met in the Emcitate® Triac Trial II study News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
24 March, 2022 Egetis receives positive EMA opinion for orphan designation of Emcitate for treatment of Resistance to Thyroid Hormone type beta (RTH-β) News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
21 March, 2022 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
21 March, 2022 Egetis Therapeutics resolves on a fully guaranteed preferential rights issue of approximately SEK 180 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
14 March, 2022 Egetis announces participation at upcoming conferences News Corporate Information Other Corporate Information English IR Optional
24 February, 2022 Egetis Therapeutics asks for hugs to increase disease awareness of MCT8 deficiency News English PR Optional mfn-cus-emcitate
18 February, 2022 FDA grants Orphan Drug Designation to Emcitate® for treatment of Resistance to Thyroid Hormone type beta (RTH-β) News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
17 February, 2022 Significant progress towards Emcitate® marketing applications in the US and Europe in 2023 News English Regulatory MAR Report Interim Yearend IR Optional
26 January, 2022 Egetis secures conditional acceptance for Emcitate® as brand name in the US News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
25 January, 2022 Egetis appoints Karl Hård as Head of Investor Relations and Communication News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
18 January, 2022 Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-deficiency could provide a basis for marketing approval for Emcitate® in the US News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-emcitate
11 January, 2022 Egetis Therapeutics gets Notice of Intent to Grant for a new European patent for a combination therapy with Aladote News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote

2021

13 December, 2021 Egetis intends to submit a marketing authorisation application for Emcitate® to the European Medicines Agency based on existing clinical data News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-emcitate
1 December, 2021 Egetis Therapeutics gets Notice of Allowance for a new US patent for a combination therapy with Aladote News Corporate Information Other Corporate Information English IR Optional
25 November, 2021 CEO and Chairman of the Board in Egetis Therapeutics acquire shares News Corporate Information Other Corporate Information English IR Optional
5 November, 2021 Nomination Committee appointed for the 2022 Annual General Meeting in Egetis Therapeutics News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
4 November, 2021 Interim report January-September 2021 News English Regulatory MAR Report Interim Q3 IR Optional
25 October, 2021 New data confirms long-term efficacy and safety of Emcitate® in MCT8 deficiency patients News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
8 October, 2021 Egetis Therapeutics receives FDA Fast Track Designation for Emcitate® for MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional mfn-cus-emcitate
29 September, 2021 Egetis Therapeutics launches disease awareness initiatives to support diagnosis of MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
PreviousNext

Calendar and upcoming reports

August 21, 2026 (7:00am CEST)
Interim Report Q2 2026

September 14-16, 2026
Morgan Stanley 24th Annual Global Healthcare Conference

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]